drugset / Trial / NCT00619398

A Study to Evaluate and Compare the Efficacy and Safety of FK506MR vs Prograf® in Stable Liver Transplantation Patients

NCT00619398

Phase 3 Completed 172 enrolled Astellas Pharma Inc
RandomizedParallel-groupOpen-labelTreatment

Summary

This study aims to evaluate and to compare the efficacy and safety of FK506MR with Prograf® in stable liver transplantation patients. It shall be demonstrated that FK506MR is non-inferior to Prograf® with regards to the efficacy and safety.

Timeline

Start
2008-01
Primary completion
2009-03
Completion
2009-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Tacrolimus Small molecule Oral

Indications

No indication recorded.